The role of striatal serotonergic terminals in L-dopa induced-dyskinesia in Parkinson's disease patients: An in vivo Positron emission tomography (PET) study

Not Applicable

Completed

• Conditions: Parkinson's disease; Nervous System Diseases

• Registration Number: ISRCTN03683971
• Lead Sponsor: Imperial College London (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-07-31
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Parkinson's disease patients and healthy individuals

Parkinson's disease patients
1. Age between 50-80
2. Were diagnosed with PD according to the UK PD Society Brain Bank criteria (Hughes et al., 1992)
3. On L-dopa treatment during the time of the study
4. Responsive to L-dopa with more than 25% reductions in Unified PD Rating Scale (UPDRS) part III motor scores
5. More than 6 months on L-DOPA
6. Non-demented [mini?mental state examination (MMSE = 26]
7. No psychiatric disorders as screened with a structured clinical interview for DSM-IV Axis I Disorders (SCID-I)
8. Do not fail screening for depression [Beck Depression Inventory - II (BDI-II) < 17; Hamilton Rating Scale for Depression (HRSD) < 14]
9. None of the subjects had received anti-depressant therapy in the past or any other medication with known action on the serotonergic system
10. No more than 1.5 body mass index (BMI) units changes over the last 12 months

Healthy individuals
1. Age between 50-80
2. Non-demented (MMSE = 26)
3. No psychiatric disorders as screened with a structured clinical interview for DSM-IV Axis I Disorders (SCID-I)
4. Do not fail screening for depression (BDI-II < 17; HRSD < 14)
5. None of the subjects had received anti-depressant therapy in the past or any other medication with known action on the serotonergic system
6. No more than 1.5 BMI units changes over the last 12 months
7. Were not on any medication
8. No previous history of neurological or psychiatric illness

Exclusion Criteria

Does not meet inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified